Affymetrix, Inc. (NASDAQ:AFFX) is introducing several new agrigenomic genotyping solutions this week at the annual Plant and Animal Genome Conference (PAG XXIV). Following the company's acquisition of Eureka Genomics in mid-2015, Affymetrix is introducing Eureka™ Genotyping Solution for low-cost, low-plex genotyping by sequencing (GBS). The company is also introducing two new array configurations for the Axiom ® genotyping platform, providing customers with a complete range of options for varying sample numbers and throughput goals.

Eureka Genotyping Solution is a new targeted genotyping by sequencing solution that delivers high throughput sample processing with low cost per sample. This is enabled by an innovative multiplexed combination of allele and sample-specific barcodes which support high sample plexing on a sequencer while delivering high quality SNP analysis. The Eureka genotyping assay overcomes the challenges associated with current GBS technologies which are susceptible to variability in genomic reads and missing SNP information, high cost, and has complex informatics analysis. Customers can access the Eureka genotyping assay as a service provided by Affymetrix Research Services Laboratory or as a kit-based product to run in their own facility.

Complementing the Eureka genotyping offerings, the new configurations of the Axiom array formats widen throughput choices for the customer. The new 24-sample configuration on the high-density Axiom 96 platform can interrogate upward of 800,000 markers while the new 96-sample configuration on the Axiom 384 HT platform can assay about 50,000 genetic variants. These new array configurations enable customers to improve the efficiency of their workflow to match sample availability and turn-around time. These new configurations extend the existing 96- and 384-sample Axiom formats available as catalog arrays off the shelf or as custom arrays delivered in six weeks or less.

"The new Eureka Genotyping Solution and Axiom array configurations allow customers to run a broad spectrum of genotyping applications from marker validation to routine screening," said Laurent Bellon, Ph.D., senior vice president and general manager, Genotyping Business Unit at Affymetrix. "Customers today are seeking flexible, high-throughput solutions that can deliver targeted, custom SNP panels containing critical 'must-have' markers associated with specific traits. The Eureka genotyping solution addresses this gap in current sequencing technologies by delivering targeted genotyping for thousands of samples per week in an easy and affordable manner."

Agricultural genotyping solutions from Affymetrix offer plant and animal genotyping scientists customized, cost-effective, automated genotyping tools for the highly accurate identification, validation, and screening of markers associated with desired genetic traits. Affymetrix is the leader in customization of agriculture genotyping arrays and also offers catalog arrays for a variety of plants and animals that were designed under the Expert Design Program.

For more information on the Axiom genotyping platform for agrigenomics applications, please visit

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness. Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.

PLEASE NOTE: Affymetrix, the Affymetrix logo, Axiom, and Eureka trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

View source version on

Copyright Business Wire 2010